The U.S. FDA says it is withdrawing the approval of 31 abbreviated new drug applications (ANDAs) held by Apotex after manufacturing deficiencies were found at two of the company’s plants. The FDA action follows Apotex’s initial request to withdraw the ANDAs in January 2018. The FDA says it became aware of concerns involving material manufactured at the two Apotex facilities, at least one of which was named in each of the pulled ANDAs. Valsartan, losartan, azithromycin and Viagra generics are among the ANDAs listed. The two facilities involved, according to the FDA, were India-based Apotex Research Private Ltd. and Apotex Pharmachem India Private Ltd. Learn More